Recent Updates
Recently added Catalysts
ALT Positive Sentiment

Altimmune to Participate in the 9th Annual Evercore Healthcare Conference

Key Takeaway: Altimmune, Inc. announced its participation in the 9th Annual Evercore Healthcare Conference on December 1, 2026. The company will engage in a fireside chat at 3:25 p.m. ET. Altimmune is advancing pemvidutide, an investigational dual receptor agonist for serious liver diseases, which has shown robust results in clinical trials.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune will participate in a notable healthcare conference.
  • Pemvidutide shows promising results in clinical trials.
  • The company is advancing therapies for serious liver diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
11.4%
average across 9 past catalysts
Cash runway
~38 mo
Low dilution risk
Lead asset
Pemvidutide
Phase 2 · Non-Alcoholic Steatohepatitis (NASH)

Full Press Release Details

MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET.
A webcast of the fireside chat will be available via the Events section of the Altimmune website.
About Altimmune Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD).For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Luis Sanay, CFA ir@altimmune.com

Media Contact: Marisa Sharkey media@altimmune.com

Frequently Asked Questions

When will Altimmune participate in the conference?

Altimmune will participate on December 1, 2026, at 3:25 p.m. ET.

What is pemvidutide?

Pemvidutide is an investigational dual receptor agonist for liver diseases.

Where can I watch the fireside chat?

The fireside chat will be available on Altimmune's website.

What diseases is pemvidutide targeting?

Pemvidutide targets serious liver diseases, including MASH and ALD.

Last updated: Nov 19, 2026